Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines

John A. Thompson; Bryan J. Schneider; Julie Brahmer; Stephanie Andrews; Philippe Armand; Shailender Bhatia; Lihua E. Budde; Luciano Costa; Marianne Davies; David Dunnington; Marc S. Ernstoff; Matthew Frigault; Benjamin H. Kaffenberger; Matthew Lunning; Suzanne McGettigan; Jordan McPherson; Nisha A. Mohindra; Jarushka Naidoo; Anthony J. Olszanski; Olalekan Oluwole; Sandip P. Patel; Nathan Pennell; Sunil Reddy; Mabel Ryder; Bianca Santomasso; Scott Shofer; Jeffrey A. Sosman; Yinghong Wang; Ryan M. Weight; Alyse Johnson-Chilla; Griselda Zuccarino-Catania; Anita Engh

doi:10.6004/jnccn.2020.0012

Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Benjamin H. Kaffenberger, Matthew Lunning, Suzanne McGettigan, Jordan McPherson, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan OluwoleSandip P. Patel, Nathan Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan M. Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, Anita Engh

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

377 Scopus citations

Abstract

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.

Original language	English (US)
Pages (from-to)	231-241
Number of pages	11
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	18
Issue number	3
DOIs	https://doi.org/10.6004/jnccn.2020.0012
State	Published - 2020

Funding

Philippe Armand, MD, PhD, Panel Member, has disclosed that he receives consulting fees from ., Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Affimed, Adaptive Biotechnologies Corp., Infinity Pharmaceuticals, ADC Therapeutics, Celgene Corporation, MorphoSys AG, Daiichi Sankyo, Inc., Miltenyi Biotec; receives grant/research support from Merck & Co., Inc., Bristol-Myers Squibb Company, Affimed, Adaptive Biotechnologies Corp., Roche, Tensha Therapeutics, Otsuka Pharmaceutical Co., Ltd, Sigma-Tau Pharmaceuticals, Inc., Genentech, Inc., and IGM Biosciences, Inc.; and receives honoraria from Merck & Co., Inc. and Bristol-Myers Squibb Company. This activity is supported by educational grants from AstraZeneca; Celgene Corporation; Coherus BioSciences; Genentech, a member of the Roche Group; and TESARO, a GSK Company. This activity is supported in part by an educational grant from Bayer Healthcare Pharmaceuticals. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc.

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2020.0012

Cite this

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Kaffenberger, B. H., Lunning, M., McGettigan, S., McPherson, J., Mohindra, N. A., Naidoo, J., Olszanski, A. J., ... Engh, A. (2020). Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 18(3), 231-241. https://doi.org/10.6004/jnccn.2020.0012

@article{7dabd3224dc34bada1e55310a80ade2d,

title = "Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines",

abstract = "The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.",

author = "Thompson, {John A.} and Schneider, {Bryan J.} and Julie Brahmer and Stephanie Andrews and Philippe Armand and Shailender Bhatia and Budde, {Lihua E.} and Luciano Costa and Marianne Davies and David Dunnington and Ernstoff, {Marc S.} and Matthew Frigault and Kaffenberger, {Benjamin H.} and Matthew Lunning and Suzanne McGettigan and Jordan McPherson and Mohindra, {Nisha A.} and Jarushka Naidoo and Olszanski, {Anthony J.} and Olalekan Oluwole and Patel, {Sandip P.} and Nathan Pennell and Sunil Reddy and Mabel Ryder and Bianca Santomasso and Scott Shofer and Sosman, {Jeffrey A.} and Yinghong Wang and Weight, {Ryan M.} and Alyse Johnson-Chilla and Griselda Zuccarino-Catania and Anita Engh",

note = "Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network",

year = "2020",

doi = "10.6004/jnccn.2020.0012",

language = "English (US)",

volume = "18",

pages = "231--241",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "3",

}

Thompson, JA, Schneider, BJ, Brahmer, J, Andrews, S, Armand, P, Bhatia, S, Budde, LE, Costa, L, Davies, M, Dunnington, D, Ernstoff, MS, Frigault, M, Kaffenberger, BH, Lunning, M, McGettigan, S, McPherson, J, Mohindra, NA, Naidoo, J, Olszanski, AJ, Oluwole, O, Patel, SP, Pennell, N, Reddy, S, Ryder, M, Santomasso, B, Shofer, S, Sosman, JA, Wang, Y, Weight, RM, Johnson-Chilla, A, Zuccarino-Catania, G & Engh, A 2020, 'Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 18, no. 3, pp. 231-241. https://doi.org/10.6004/jnccn.2020.0012

TY - JOUR

T1 - Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines

AU - Thompson, John A.

AU - Schneider, Bryan J.

AU - Brahmer, Julie

AU - Andrews, Stephanie

AU - Armand, Philippe

AU - Bhatia, Shailender

AU - Budde, Lihua E.

AU - Costa, Luciano

AU - Davies, Marianne

AU - Dunnington, David

AU - Ernstoff, Marc S.

AU - Frigault, Matthew

AU - Kaffenberger, Benjamin H.

AU - Lunning, Matthew

AU - McGettigan, Suzanne

AU - McPherson, Jordan

AU - Mohindra, Nisha A.

AU - Naidoo, Jarushka

AU - Olszanski, Anthony J.

AU - Oluwole, Olalekan

AU - Patel, Sandip P.

AU - Pennell, Nathan

AU - Reddy, Sunil

AU - Ryder, Mabel

AU - Santomasso, Bianca

AU - Shofer, Scott

AU - Sosman, Jeffrey A.

AU - Wang, Yinghong

AU - Weight, Ryan M.

AU - Johnson-Chilla, Alyse

AU - Zuccarino-Catania, Griselda

AU - Engh, Anita

PY - 2020

Y1 - 2020

N2 - The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.

AB - The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.

UR - http://www.scopus.com/inward/record.url?scp=85081374182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081374182&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2020.0012

DO - 10.6004/jnccn.2020.0012

M3 - Article

C2 - 32135517

AN - SCOPUS:85081374182

SN - 1540-1405

VL - 18

SP - 231

EP - 241

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 3

ER -

Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this